Skip to main content
. Author manuscript; available in PMC: 2021 Jun 2.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2017 Aug 1;20(4):436–441. doi: 10.1038/pcan.2017.34

Figure 1.

Figure 1.

(a) Rates of clinically significant prostate cancer detection over the course of 10-year experience, comparing trends from mpMRI-TRUS fusion-guided biopsy, systematic 12-core biopsy, and combined mpMRI-TRUS fusion-guided biopsy/systematic 12-core biopsy. Patients were stratified by date of biopsy into corresponding time cohort. There was a significant increase (P < 0.001) in detection of clinically significant prostate cancer by mpMRI-TRUS fusion-guided biopsy with each successive cohort: 24.8% (57/230) in cohort 1, 31.5% (169/537) in cohort 2 and 36.4% (277/761) in cohort 3 (χ2-test). (b) Age and PSA adjusted rates of clinically significant prostate cancer detection over the course of 10-year experience, comparing trends from mpMRI-TRUS fusion-guided biopsy, systematic 12-core biopsy and combined mpMRI-TRUS fusion-guided biopsy/systematic 12-core biopsy. Cancer detection rate of mpMRI-TRUS fusion-guided biopsy demonstrated significant increases in each successive cohort (cohort 2 vs 1: increase by 5.2%, 95% CI (2.1–8.5), P = 0.001), 3 vs 2 (increase by 5.2%, 95% CI (1.8–8.6), P = 0.003).